ThermoGenesis Holdings to Present at the H.C. Wainwright BioConnect Virtual Conference

Rhea-AI Summary

ThermoGenesis Holdings, Inc. (Nasdaq: THMO) announced that CFO Jeff Cauble will present a company overview at the H.C. Wainwright BioConnect Virtual Conference from January 10-13, 2022. The presentation will be available on their website for on-demand viewing and will be archived for 90 days. ThermoGenesis specializes in automated cell processing technologies for CAR-T and cell-based therapies, offering solutions for clinical biobanking and immuno-oncology applications. For more details, visit their website.

News Market Reaction – THMO

+7.39%

+7.39% Session move

In the trading session that priced this news, THMO gained 7.39%, reflecting a notable positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

RANCHO CORDOVA, Calif., Jan. 10, 2022 /PRNewswire/ -- ThermoGenesis Holdings, Inc. (Nasdaq: THMO), a market leader in automated cell processing tools and services in the cell and gene therapy field, today announced that Chief Financial Officer, Jeff Cauble, will present a company overview at the H.C. Wainwright BioConnect Virtual Conference taking place January 10-13, 2022.

The on-demand presentation is available for viewing on ThermoGenesis' website at: https://thermogenesis.com/investors/news-and-events/events-webcasts/ and will be archived for a period of 90 days following the event.

About ThermoGenesis Holdings, Inc.
ThermoGenesis Holdings, Inc. develops, commercializes, and markets a range of automated technologies for CAR-T and other cell-based therapies. The Company currently markets a full suite of solutions for automated clinical biobanking, point-of-care applications, and automation for immuno-oncology, including its semi-automated, functionally-closed CAR-TXpress™ platform, which streamlines the manufacturing process for the emerging CAR-T immunotherapy market. For more information about ThermoGenesis, please visit: www.thermogenesis.com.

Company Contact:
Wendy Samford
916-858-5191
ir@ThermoGenesis.com

Investor Contact:
Paula Schwartz, Rx Communications
917-322-2216
pschwartz@rxir.com

 

View original content:https://www.prnewswire.com/news-releases/thermogenesis-holdings-to-present-at-the-hc-wainwright-bioconnect-virtual-conference-301456955.html

SOURCE ThermoGenesis Holdings, Inc.

FAQ

When will ThermoGenesis Holdings present at the H.C. Wainwright BioConnect Virtual Conference?

ThermoGenesis Holdings will present from January 10-13, 2022.

Who is presenting for ThermoGenesis Holdings at the conference?

CFO Jeff Cauble will present an overview of the company.

Is the presentation available for later viewing?

Yes, the presentation will be available on-demand on ThermoGenesis' website and archived for 90 days.

What technologies does ThermoGenesis Holdings develop?

ThermoGenesis develops automated technologies for CAR-T and other cell-based therapies, including their CAR-TXpress™ platform.

Where can I find more information about ThermoGenesis Holdings?

More information is available on their official website at www.thermogenesis.com.